Update of the treatment of multisystem inflammatory syndrome in children (mis -c) associated with SARS - COV2
Article Sidebar
Main Article Content
Abstract
Background: Pediatric multisystem inflammatory syndrome (mis - c) associated with SARS- CoV-2 is a syndrome derived from a primary complication of COVID-19 infection, which can present within the acute phase or in the convalescent phase of the disease. Objective: to update the available evidence on the treatment of this syndrome. Methods: A search for information was carried out in the databases PubMed, Scielo, Cochrane, Science Direct and Google Scholar. A targeted search strategy was used for each database with the keywords: "MISC"; "pediatric multi-system inflammatory syndrome" "COVID 19" "treatment" considering the cut-off years from 2020 to 2023. Analytical and review observational articles were included. Results: 30 studies were included, it is concluded that immunomodulatory treatment is the treatment of choice in patients with MIS-C with antiplatelet therapy being the supportive treatment for the patient. Discussion: No case reports or clinical trials were included so studies are required to expand the available evidence. Others: This study did not receive external funding.
Downloads
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Creative Commons
License Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0)
You are free to:
Share - copy and redistribute the material in any medium or format.
Adapt - remix, transform, and build upon the material The licensor cannot revoke these freedoms as long as you follow the license terms.
• Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
• NonCommercial — You may not use the material for commercial purposes.
• ShareAlike — If you remix, transform, or build upon the material, you must distribute your contributions under the same license as the original.
• No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
References
Qiu H., Wu J., Hong L. Clinical and epidemiological features of 36 children with coronavirus disease 2019 (COVID-19) in Zhejiang, China: an observational cohort study. Lancet Infect Dis. 2020; 5(2):14-18.
La Torre F, Taddio A, Conti C, Cattalini M. Multi-Inflammatory Syndrome in Children (MIS-C) in 2023: Is It Time to Forget about It? Children (Basel). 2023 May 31;10(6):980. doi: 10.3390/children10060980. PMID: 37371212; PMCID: PMC10297102. Montaño-Luna VE, Miranda-Novales MG. Actualización del manejo clínico de COVID-19 en pediatría: a un año de pandemia. Rev Mex Pediatría [Internet]. 7 de mayo de 2021 [citado 7 de diciembre de 2023];88(1):31-45. Disponible en: https://www.medigraphic.com/cgi-bin/new/resumen.cgi?IDARTICULO=99417 .
Kim H, Shim JY, Ko JH, Yang A, Shim JW, Kim DS, et al. Multisystem inflammatory syndrome in children related to COVID-19: the first case in Korea. J Korean Med Sci 2020;35:e391-8.
Jain S, Sen S, Lakshmivenkateshiah S, Bobhate P, Venkatesh S, Udani S, et al. Multisystem inflammatory syndrome in children with COVID-19 in Mumbai, India. Indian Pediatr 2020;57:e1015-9.
Mamishi S, Movahedi Z, Mohammadi M, Ziaee V, Khodabandeh M, Abdolsalehi MR, et al. Multisystem inflammatory syndrome associated with SARS-CoV-2 infection in 45 children: a first report from Iran. Epidemiol Infect 2020;148:e196.
Moraleda C, Serna-Pascual M, Soriano-Arandes A, Simo S, Epalza C, Santos M, et al. Multi-inflammatory syndrome in children related to SARS-CoV-2 in Spain. Clin Infect Dis 2020;ciaa1042.
Molloy EJ, Nakra N, Gale C, Dimitriades VR, Lakshminrusimha S. Multisystem inflammatory syndrome in children (MIS-C) and neonates (MIS-N) associated with COVID-19: optimizing definition and management. Pediatr Res [Internet]. mayo de 2023 [citado 7 de diciembre de 2023];93(6):1499-508. Disponible en: https://www.nature.com/articles/s41390-022-02263-w
Antunez O. COVID-19 and multisystem inflammatory syndrome in Latin American children: a multinational study. Pediatr Infect Dis J 2021;40:e1-6.
Rowley AH. Understanding SARS-CoV-2-related multisystem inflammatory syndrome in children. Nat Rev Immunol 2020;20:453-4.
Verdoni L., Mazza A., Gervasoni A. An outbreak of severe Kawasaki-like disease at the Italian epicentre of the SARS-CoV-2 epidemic: an observational cohort study. Lancet. 2020; 6(2):14-16.
Riphagen S., Gomez X., Gonzalez-Martinez C., Wilkinson N., Theocharis P. Hyperinflammatory shock in children during COVID-19 pandemic. Lancet. 2020; 6: (20)31094-1.
Londoño-Martinez J. Consenso colombiano de atención, diagnóstico y manejo de la infeccioón por SARS-Cov-2/COVID 19 en establecimientos de atención de la salud [Internet]. Revista de la asociación colombiana de infectología.; 2021 [citado 6 de diciembre de 2023]. Disponible en:
https://www.acin.org/index.php/publicaciones/consenso-colombiano-de-atencion
Gottlieb M, Bridwell R, Ravera J, Long B. Multisystem inflammatory syndrome in children with COVID-19. Am J Emerg Med. 2021 Nov;49:148-152.
Hee J. Clinical features, diagnosis, and outcomes of multisystem inflammatory syndrome in children associated with coronavirus disease Clin Exp Pediatr 2019; 64 (2): 68–75.
Kwak, J. H., Lee, S. Y., Choi, J. W., & Korean Society of Kawasaki Disease (2021). Clinical features, diagnosis, and outcomes of multisystem inflammatory syndrome in children associated with coronavirus disease 2019. Clinical and experimental pediatrics, 64(2), 68–75.
Hennon T. COVID-19 associated Multisystem Inflammatory Syndrome in Children (MIS-C) guidelines; a Western New York approach. Prog Pediatr Cardiol. 2020; 23 : 101232.
Henderson LA, Canna SW, Friedman KG, Gorelik M, Lapidus SK, Bassiri H, et al. American college of rheumatology clinical guidance for multisystem inflammatory syndrome in children associated with SARS-CoV-2 and hyperinflammation in pediatric COVID-19: version 1. Arthritis Rheumatol. (2020) 72:1791–805.
Cron R.Q., Chatham W.W. The rheumatologist’s role in COVID-19. J Rheumatol. 2020;47(5):639–642.
Fouriki A, Fougère Y, De Camaret C, Blanchard Rohner G, Grazioli S, Wagner N, Relly C, Pachlopnik Schmid J, Trück J, Kottanatu L, Perez E, Perez M-H, Schaffner D, Asner SA and Hofer M. Case Report: Case Series of Children With Multisystem Inflammatory Syndrome Following SARS-CoV-2 Infection in Switzerland. Front. Pediatr 2021; 8:594127.
Pouletty M. Paediatric multisystem inflammatory syndrome temporally associated with SARS-CoV-2 mimicking Kawasaki disease (Kawa-COVID-19): a multicentre cohort. Ann Rheum Dis 2020;79:999–1006.
Klok F. Confirmation of the high cumulative incidence of thrombotic complications in critically ill ICU patients with COVID-19: an updated analysis. Thromb Res. 2020 Apr 30 doi: 10.1016/j.thromres.2020.04.041.
Ye Q. The pathogenesis and treatment of the ‘Cytokine Storm’ in COVID-19. J Infect. 2020;80(6):607–613.
Santos, M. O., Gonçalves, L. C., Silva, P. A. N., Moreira, A. L. E., Ito, C. R. M., Peixoto, F. A. O., Multisystem inflammatory syndrome (MIS-C): a systematic review and meta-analysis of clinical characteristics, treatment, and outcomes. Jornal de pediatria, 2022; 98(4): , 338–349.
Pouletty M. Paediatric multisystem inflammatory syndrome temporally associated with SARS-CoV-2 mimicking Kawasaki disease (Kawa-COVID-19): a multicentre cohort. Ann Rheum Dis 2020;79:999–1006. .
- Mc Ardle A. Treatment of Multisystem Inflammatory Syndrome in Children. N Engl J Med 2021; 385:11-22.
Ouldali N. Association of Intravenous Immunoglobulins Plus Methylprednisolone vs Immunoglobulins Alone With Course of Fever in Multisystem Inflammatory Syndrome in Children. JAMA. 2021;325(9):855-864.
- Haneen K. COVID-19 in children: an approach for multisystem infammatory syndrome. Egypt Pediatric Association Gaz 2021; 69:33. .
- Licciardi F, Baldini L, Dellepiane M, Covizzi C, Mogni R, Pruccoli G, Orsi C, Rabbone I, Parodi E, Mignone F and Montin D. MIS-C Treatment: Is IVIG Always Necessary? Front. Pediatr. 2021; 9:753123.
- Vukomanovic R. Recent Experience: Corticosteroids as a First-line Therapy in Children With Multisystem Inflammatory Syndrome and COVID-19-related Myocardial Damage. Pediatr Infect Dis J 2021;40(11):e390-e394.
- Belhadjer J. Addition of Corticosteroids to Immunoglobulins Is Associated With Recovery of Cardiac Function in Multi-Inflammatory Syndrome in Children. Circulation 2020; 142 (23): 2282-2284.
- Abdel N. SARS-CoV-2-associated multisystem inflammatory syndrome in children: clinical manifestations and the role of infliximab treatment. Eur J Pediatr. 2021; 16 : 1–11.
Kaushik A. A Systematic Review of Multisystem Inflammatory Syndrome in Children Associated With SARS-CoV-2 Infection. Pediatr Infect Dis J 2020;39:e340–e346.
Cieza-Yamunaqué, L., Rodríguez-Portilla, R., Baique-Sánchez, M. Evolution and management of the pediatric multi-systemic inflammatory syndrome associated with SARS CoV-2 infection in a pediatric ICU in Lima, Peru. Rev. Cuerpo Med. HNAAA, Vol 14 (3) – 2021, 262 – 266.
Liz E. De Coll-Vela, Mariela K. Zamudio-Aquise, Héctor Nuñez-Paucar. Covid-19–associated multisystem inflammatory syndrome in children: case series at a pediatric hospital in Perú. Rev Peru Med Exp Salud Publica. 2020;37(3):559-65.